Tatsuya Yoshida

Tatsuya Yoshida

Auto-generated profile, based on publicly available information

Tatsuya Yoshida

Department of Breast Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Kanagawa, Japan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1994 in Journal of Endodontics
Verified
Journal Article
Closed access
PDF file
KHKazuko Hashioka
Kazuko Hashioka
KSKazuyoshi Suzuki
Kazuyoshi Suzuki
TYTsutomu Yoshida
Tsutomu Yoshida
ANAkinobu Nakane
Akinobu Nakane
NHNaoki Horiba
Naoki Horiba
HNHiroshi Nakamura
Hiroshi Nakamura

1 January 2006 in Industrial Health
Verified
Journal Article
Open access
PDF file
KNKaoru Nagaoka
Kaoru Nagaoka
TYTsutomu Yoshida
Tsutomu Yoshida
HSHiroki Sakakibara
Hiroki Sakakibara
HKHideki Kurita
Hideki Kurita
HTHiroshige Taniwaki
Hiroshige Taniwaki
YOYuichiro Ono
Yuichiro Ono
Chronic beryllium disease (CBD) is a rare disease characterized by diffuse interstitial pulmonary granulomatosis. We report a case of CBD which exhibited marked improvement both subjectively and objectively following pulse therapy. The patient was a 36-year-old man whose chief complaint was dyspnea and a dry cough. Since July 1990, the patient had been working in the development of an automatic or mechanical technique for producing beryllium-copper alloy. It appeared likely that the patient may have been exposed to metal beryllium fumes generated from an opening located just above the furnace. The Be concentration exceeded 25 μg/m3 transiently in the breathing zone in this workplace. A chest X-ray film taken in October 1994 showed fine granular shadows throughout the entire lung fields. Around August 1998, the patient's dyspnea became aggravated. An X-ray taken at that time showed linear and reticular shadows, in addition to the diffuse fine granular shadow. In October 1998, after 3 days of methylprednisolone pulse therapy, oral prednisolone 30 mg was initiated. With this treatment, the patient's pulmonary function tests and blood gases improved. Once the patient's condition had improved sufficiently, the dosage of prednisolone was decreased by 2.5 mg every two weeks. The patient continues to be monitored.

1 January 2023 in Endocrinology, Diabetes & Metabolism Case Reports
Verified
Journal Article
Open access
PDF file
MTMadoka Toyoda
Madoka Toyoda
NSNobuyasu Suganuma
Nobuyasu Suganuma
ATAkari Takahashi
Akari Takahashi
TMTaku Masuda
Taku Masuda
MGMasami Goda
Masami Goda
MMMunetaka Masuda
Munetaka Masuda
Summary: Emergencies due to malignancies usually have a severe clinical course and require urgent treatment. These scenarios are dubbed ‘oncologic emergencies’. Parathyroid tumours often cause hypercalcaemia but not oncologic emergencies. We present a case of parathyroid carcinoma with severe hypercalcaemia and pancreatitis, resolved by surgical resection of the tumour assisted by extracorporeal membrane oxygenation (ECMO). A 66-year-old woman presented to our hospital because of haematuria. Laboratory findings were as follows: white blood cell count: 30 000, C-reactive protein: 17.7, calcium: 21.9, creatine kinase: 316, creatine kinase-myoglobin binding: 20, troponin I: 1415.8, amylase: 1046, lipase: 499, blood urea nitrogen: 57, and creatinine: 2.42. ECG was unremarkable. CT revealed a 4-cm low-density irregular tumour in the left lobe of the thyroid gland and severe pancreatitis. We diagnosed hypercalcaemia and pancreatitis due to parathyroid carcinoma. Volume expansion with isotonic saline was started immediately. Calcitonin, followed by denosumab, calcimimetic agents, and continuous hemodiafiltration were administered. The patient’s general condition worsened due to uncontrolled hypercalcaemia. Urgent tumour resection was planned, assisted with ECMO for cardiopulmonary support and surgical field venous pressure reduction. Tumour histology was suggestive of parathyroid carcinoma. Hypercalcaemia and the patient’s general condition improved gradually postoperatively. Hypercalcaemia is one of the oncologic emergency symptoms, commonly occurring because of lytic bone metastasis. However, reports about parathyroid carcinoma-causing life-threatening hypercalcaemia and pancreatitis are scarce; the fatality of this condition is estimated to be 30–70%. We report a case of survival of hypercalcaemia of malignancy. Learning points: Parathyroid carcinoma is relatively rare and sometimes causes emergent conditions such as hypercalcaemia and severe pancreatitis. General therapy for hypercalcaemia including aggressive saline dehydration, administration of furosemide, calcitonin, zoledronic acid, and evocalcet, and dialysis is sometimes ineffective for parathyroid carcinoma. Therefore, careful planning of therapy in case of exacerbation is important. During an emergency, rapid surgical treatment despite high calcium level is the best potential therapeutic strategy.

15 April 2026 in Breast Cancer Research
Verified
Journal Article
Open access
TYTatsuya Yoshida
Tatsuya Yoshida
FWFeifei WEI
Feifei WEI
TKTaku Kouro
Taku Kouro
KKKosuke Kawaguchi
Kosuke Kawaguchi
TKTatsuki Kataoka
Tatsuki Kataoka
Tetsuro SasadaTetsuro Sasada
Tetsuro Sasada
Neoadjuvant chemotherapy (NAC) with anti-HER2 agents is standard for HER2-positive breast cancer, achieving pathological complete response (pCR) in 40–50% of patients; however, reliable predictors of response remain limited. HER2 is an immunogenic antigen capable of eliciting humoral responses, yet the predictive value of HER2-specific autoantibodies in the neoadjuvant setting remains unclear. We investigated whether HER2-peptide–specific antibody responses could serve as potential biomarkers of treatment response. Paired pre- and post-NAC sera from 112 patients enrolled in the JBCRG-16 (Neo-Lath) trial, which evaluated trastuzumab- and lapatinib-containing NAC, were analyzed. IgG titers against 63 non-overlapping 20-mer HER2-derived peptides were measured using a multiplex bead array, and serum HER2 protein levels were also quantified. Data were analyzed using Wilcoxon signed-rank and rank-sum tests, Spearman’s correlation analyses, and univariate logistic regression for pCR. Predictive models were constructed using elastic net regression with nested cross-validation across pretreatment, posttreatment, and fold-change datasets, and model performance was assessed by the area under the receiver operating characteristic curve (AUC). HER2-derived peptides elicited heterogeneous immune responses, and IgG titers against 37 of 63 peptides (58.7%) significantly decreased after NAC. Pretreatment IgG titers were positively correlated with the Boman index and negatively correlated with the aliphatic index. In univariate analyses, neither IgG titers nor serum HER2 levels at either time point, nor their treatment-induced changes, were significantly associated with pCR. In contrast, a predictive model based on treatment-induced changes in a subset of peptide-specific IgG titers demonstrated consistent predictive performance (AUC 0.78 in training and 0.79 in validation). Six peptides distributed across the HER2 sequence contributed to pCR prediction. Dynamic changes in HER2-peptide-specific autoantibodies during NAC, rather than static titers alone, may provide informative biomarkers for predicting clinical response. Serum HER2 levels were not significantly associated with pCR, suggesting that autoantibody profiling may capture response-related biology not reflected by antigen levels alone. These findings provide proof-of-concept evidence that minimally invasive, longitudinal profiling of peptide-specific autoantibodies could complement established response-assessment modalities, such as imaging or molecular assays. However, these results are exploratory and require validation in larger, independent cohorts before clinical application. UMIN000007576 (Registration date: March 26, 2012). The online version contains supplementary material available at 10.1186/s13058-026-02259-y.